Navigation Links
Codiak BioSciences Closes $61 Million Series B Financing
Date:1/26/2016

CAMBRIDGE, Mass., Jan. 26, 2016 /PRNewswire/ -- Codiak BioSciences Inc., a leading company in the field of exosome biology, today announced the closing of its $61 million Series B round, bringing total investment in its combined Series A and B financing, announced in November 2015, to $92 million. Codiak intends to use the proceeds of this round primarily to advance research and clinical development of exosomes for therapeutic and diagnostic purposes. 

The Series A and B financing were co-led by ARCH Venture Partners and Flagship Ventures, with participation by the Alaska Permanent Fund, Alexandria Venture Investments and Fidelity Management and Research Company.

"This financing is a strong indication of the promise of exosomes to improve human health," said Douglas E. Williams, Ph.D., President and CEO. "With these additional resources we will continue to build our world-class team to realize the broad transformative potential of exosomes for multiple therapeutic and diagnostic uses."

About Exosomes

Exosomes are tiny membrane sacs, or vesicles, that are released by both healthy and cancerous cells. Substances from cell cytoplasm, including genomic DNA, various RNA species, proteins and lipids are encapsulated into exosomes and are shed into the extracellular environment. All fluids in the human body have been shown to contain exosomes, which can transfer the cytoplasmic ingredients to other cells either locally or at distant sites. The cytoplasmic payload within exosomes, once transferred to the recipient cells, can alter the biology of the recipient cells. Exosomes may be useful for diagnostic purposes since they contain genomic DNA for mutational analysis using a simple blood test. In addition, cancer-derived exosomes have specific markers that enable them to be isolated, purified and analyzed. Exosomes have been described as the package delivery system of the body because of their ability to be released from one cell and deliver their contents to distant cells. This property of exosomes may play an essential role in the formation of certain microenvironments in health and disease.

About Codiak

Codiak BioSciences is a venture-backed start-up dedicated to harnessing the power of exosomes as both therapeutics and diagnostics in cancer and other diseases. Codiak is building a world-class team and has generated, acquired and licensed foundational intellectual property to enable the development of products that capitalize on the unique biology of exosomes.

Contact:
Daniel McIntyre
617-716-9107
dan@publickhousegroup.com

Logo - http://photos.prnewswire.com/prnh/20160104/318954LOGO


'/>"/>
SOURCE Codiak BioSciences Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. ARCH Venture Partners, Flagship Ventures and MD Anderson Collaborate to Launch Codiak BioSciences
2. Kuros Biosurgery Holding Ltd. Closes Merger With Cytos Biotechnology Ltd. Which is Renamed Kuros Biosciences Ltd.
3. Profectus BioSciences Initiates Ebola Vaccine Phase 1 Clinical Trial
4. Lucerne Biosciences Completes Sourcing Investigation into Shires IPR that Led to the Invalidation of the 813 Patent
5. ARMO BioSciences to Present at the 34th Annual J.P. Morgan HealthCare Conference
6. Kindred Biosciences to Provide Corporate Update
7. Sangamo BioSciences Announces Presentation At The 34th Annual J.P. Morgan Healthcare Conference
8. Imago BioSciences Announces Preclinical Data on LSD1 Inhibitor at Annual Meeting of the American Society of Hematology (ASH)
9. Cytos Biotechnology and Kuros Biosurgery to Combine to Create Kuros Biosciences
10. Neurocrine Biosciences to Present at the 27th Annual Piper Jaffray Healthcare Conference
11. Representative Scott Peters Visits Avelas Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/3/2019)... ... October 02, 2019 , ... Rapid ... pleased to announce that it has moved into a new, 5000 sqft, purpose-built, ... the new facility demonstrates the company's continuous commitment to quality research and service ...
(Date:9/24/2019)... ... 2019 , ... Drug resistance has been declared as one of the biggest ... one of the most serious concerns. Hong Kong cannot be spared from the worsening ... or a seven-fold of the figure in 2007 – the year the disease became ...
(Date:9/24/2019)... ... ... In the past three years, the National Science Foundation (NSF) has awarded ... of Mines & Technology that expands human understanding of the microbial world. The ... and yet strong layer which is commonly known as a biofilm. , The broad ...
(Date:9/17/2019)... ... September 17, 2019 , ... Geneticure, Inc., a Rochester ... today that the U.S. Patent and Trademark Office (USPTO) and European Patent Office ... class recommendations for hypertension treatment. , The patent applies to Geneticure’s first ...
Breaking Biology Technology:
(Date:10/3/2019)... ... ... Personalized Stem Cells, Inc (“PSC”), a human adipose-derived stem cell company, ... stem cell treatment of knee osteoarthritis . The successful enrollment comes only a little ... Biopharma. , PSC CEO, Michael Dale, stated, “We are proud that as we celebrate ...
(Date:9/30/2019)... ALTO, Calif. (PRWEB) , ... September 30, 2019 ... ... public interest organization focused on molecular manufacturing and other transformative technologies, announced the ... categories, one for Experiment and the other for Theory in nanotechnology/molecular manufacturing. , ...
(Date:9/30/2019)... ... September 30, 2019 , ... As human induced pluripotent stem cells (hiPSCs) ... the development and diseases of the human heart, there is an increasing need for ... muscle cells to be clearly and easily recorded. A study released today in STEM ...
Breaking Biology News(10 mins):